Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126 ·Status: RECRUITING ·Phase: PHASE2

Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis

NCT06521762 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

NCT02100696 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

NCT04996797 ·Status: COMPLETED ·Phase: PHASE2

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT04176588 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis

NCT07243639 ·Status: RECRUITING ·Phase: NA

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

NCT05061446 ·Status: COMPLETED ·Phase: PHASE2

An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

NCT03362736 ·Status: NO_LONGER_AVAILABLE

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

NCT03996369 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

NCT02249078 ·Status: WITHDRAWN ·Phase: PHASE1

Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment

NCT06867042 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis

NCT00729872 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Expanded Access to Risankizumab

NCT03914261 ·Status: NO_LONGER_AVAILABLE

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

NCT01461317 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

NCT03808103 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients

NCT03100864 ·Status: COMPLETED ·Phase: PHASE2

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

NCT01620255 ·Status: COMPLETED ·Phase: PHASE2

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

NCT01221818 ·Status: COMPLETED ·Phase: PHASE1

Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

NCT01961492 ·Status: WITHDRAWN ·Phase: NA

An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease

NCT00269841 ·Status: COMPLETED ·Phase: PHASE3

A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

NCT00787202 ·Status: COMPLETED ·Phase: PHASE2

PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial

NCT06301477 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06049017 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors

NCT02136069 ·Status: COMPLETED ·Phase: PHASE3